Articles

Poll

Podcasts

Slideshows

Videos

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

The rheumatology month in review emphasizes new research in gout burden, fibromyalgia management, and innovative lupus treatments.

Rheumatology Month in Review: May 2025

Epaminurad effectively lowers serum uric acid levels in gout patients, showing promise as a safe and tolerable treatment option.

hURAT1 Inhibitor Epaminurad Safely Reduces Serum Uric Acid in People With Gout

New research highlights Lipid Accumulation Product as a key predictor for gout and hyperuricemia, offering a modifiable risk factor for prevention.

LAP May Predict Risk of Hyperuricemia and Gout 

A new study reveals semaglutide's protective effects against osteoporosis and gout in obese individuals with type 2 diabetes, enhancing metabolic health insights.

Semaglutide Protects Against Osteoporosis, Gout, in People With Obesity and Type 2 Diabetes

Notably, nearly 1/3 of study participants used opioids over a 12-month follow-up period, indicating significant pain.

Chronic Refractory Gout Needs Better Management in US

Adolescent gout rates are rising globally, highlighting the need for early intervention and lifestyle changes to mitigate health risks.

Global Rates of Gout Rising in Young Adults 

A new study utilizing machine learning reveals how physical activity reduces gout risk in people with hyperuricemia.

Physical Activity and Sedentary Time Top Factors for Gout Risk in People With Hyperuricemia

A recent study reveals a significant prevalence of gout in end-stage renal disease patients, highlighting the complex relationship between kidney function and uric acid levels.

Gout Prevalence High Among Patients With End-Stage Renal Disease 

Pegloticase treatment significantly improves serum urate levels and quality of life in kidney transplant recipients with gout, showing promising clinical benefits.

Pegloticase Managed Gout, Improved QoL Measures in Kidney Transplant Recipients

Febuxostat was associated with a nearly 3-fold higher risk of mild to moderate perturbation of liver function than benzbromarone.

Higher Hepatotoxicity Risk With Febuxostat Over Benzbromarone in People With Gout

On the HCPLive gout page, resources on the topics of medical news and expert insight into gouty arthritis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on gout, and more.